PurMinds Enterprises, Inc., formerly Pacific Software, Inc., is a precision neuro-medicine development company pursuing solutions to neurological and psychiatric disorders. The Company's clinical pipeline includes neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. The Company is focused on a 4P Medicine platform, in strategic partnership with SpectroChip Global Inc., for early detection and intervention of conditions before irreversible damage occurs. The Company operates under a Health Canada issued Controlled Drugs and Substances License. It has developed a pipeline of proprietary formulations and novel small molecules (NCEs). The Company's pipeline includes PUR100 Series and PUR500 Series.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-13	US$0.0570	-5.00%	114,000
26-08-12	US$0.0600	-.--%	114,000
26-08-11	US$0.0600	+9.09%	162,812
26-08-10	US$0.0550	-1.79%	82,000
26-08-07	US$0.0560	+38.27%	2,000

Real-time OTC Markets

More quotes

Real-time OTC Markets 09:52:32 2026-05-18 EDT			5-day change	1st Jan Change
0.0400 ^USD	-11.11%		-1.23%	-66.67%

06-10	Purminds Enterprises, Inc. Announces CFO Changes	CI
06-10	PurMinds Enterprises, Inc. Announces Appointment of Angelo Pizzuto as Chief Operating Officer, Secretary, and Treasurer, Effective June 10, 2026	CI

Market Cap	48.82M 42.17M 39.62M 36.04M 67.75M 4.67B 68.87M 464M 182M 2.34B 183M 179M 7.77B	P/E 2019	-2.65x	P/E 2020	-41.2x
Enterprise Value	49.19M 42.49M 39.92M 36.31M 68.26M 4.7B 69.39M 468M 183M 2.36B 185M 181M 7.83B	EV / Sales 2019	-	EV / Sales 2020	2,435,972,350x
Free-Float	99%	Yield 2019 *	-	Yield 2020	-

06-10	Purminds Enterprises, Inc. Announces CFO Changes	CI
06-10	PurMinds Enterprises, Inc. Announces Appointment of Angelo Pizzuto as Chief Operating Officer, Secretary, and Treasurer, Effective June 10, 2026	CI
11-11	Pacific Software Inc Announces Exclusive Partnership with SpectroChip Global Inc	CI
11-10	Pacific Software, Inc. acquired 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc.	CI
25-08-26	Pacific Software, Inc. agreed to acquire 10763942 Canada Inc. and PurMinds Asset Portfolio from PurMinds NeuroPharma Inc.	CI
24-07-22	Robert Schiestl Joins Pacific Software Inc. as Chief Science Advisor	CI
24-05-05	Pacific Software, Inc. acquired Certain assets of Dreamaderm Inc. from Dreamaderm Inc.	CI
21-01-24	Pacific Software, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	CI
20-12-16	Pacific Software, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019	CI
20-12-16	Pacific Software, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020	CI
19-06-18	Pacific Software, Inc. Reports Earnings Results for the Full Year Ended September 30, 2018	CI
19-06-06	Pacific Software Inc. Enters into Memorandum of Understanding with Império Assessoria em Informaçoes LTDA	CI
19-05-12	Pacific Software, Inc. completed the spin-off of Hypersoft Ventures.	CI

01-19	Pacific Software, Inc. Announces Completion of Change of Control with PurMinds Holdings Inc.; Confirms Occupancy of a GMP Production Facility; and OTCQX Uplisting Strategy	PR
11-11	Pacific Software Inc Announces Exclusive Partnership with SpectroChip Global	PR
25-08-27	Pacific Software Inc Acquires 10763942 Canada, Inc. from PurMinds Holdings Inc., Including its PurMinds Products and Research Partners	AQ
24-07-22	Professor Dr. Robert Schiestl Ph. D. Joins Pacific Software Inc. as Chief Science Advisor (CSA)	GL
24-06-28	Pacific Software Inc. Obtaining Quotes for the Manufacturing Cycle for Scientifically Tested Medical Food Cocktail Focused on Memory Health	GL

Pacific Software, Inc. Stock

Stocks

PFSF

US69482P2056

Biotechnology & Medical Research

Valuation: Pacific Software, Inc.

Chart: Pacific Software, Inc.

Latest news : Pacific Software, Inc.

Press Releases: Pacific Software, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Pacific Software, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-11.11%
1 week	-1.23%
Current month	-20.00%
1 month	-20.00%
3 months	-4.76%
6 months	-20.00%
Current year	-66.67%

1 week	0.04	0.06
1 month	0.04	0.06
Current year	0.03	0.09
1 year	0.01	0.12
3 years	0	0.3
5 years	0	2.83
10 years	0	5.59

Manager	Title	Age	Since
Janet Qi CEO	Chief Executive Officer	-	-
Angelo Pizzuto DFI	Director of Finance/CFO	-	2026-06-09

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PACIFIC SOFTWARE, INC.	-11.11%	-1.23%	+669.23%	-21.57%	3.56M
LONZA GROUP AG	-1.78%	-1.68%	+1.99%	+13.84%	49.24B
REVOLUTION MEDICINES, INC.	+0.04%	-1.78%	+459.38%	+571.63%	43.3B
BEONE MEDICINES AG	-2.63%	-0.65%	+11.73%	+69.51%	40.48B
IQVIA HOLDINGS INC.	-1.60%	-0.45%	+25.46%	+7.95%	39.75B
CELLTRION, INC.	-0.50%	+3.08%	+19.91%	+47.26%	32.67B
ASCENDIS PHARMA A/S	-0.27%	-3.62%	-	-	16.23B
MEDPACE HOLDINGS, INC.	-0.77%	-1.62%	+26.69%	+118.77%	16.24B
EUROFINS SCIENTIFIC SE	+0.49%	+0.92%	+4.32%	+22.16%	14.04B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.55%	+3.50%	+77.69%	+27.64%	13.43B
Average	-1.97%	+1.94%	+144.05%	+95.24%	26.54B
Weighted average by Cap.	-1.17%	+2.54%	+94.98%	+131.31%

	2019	2020
Net sales	-	0.02 0.02 0.02 0.01 0.03 1.91 0.03 0.19 0.07 0.96 0.08 0.07 3.18
Net income	-21.11M -18.23M -17.13M -15.58M -29.3M -2.02B -29.78M -201M -78.5M -1.01B -79.26M -77.54M -3.36B	-1.17M -1.01M -953K -867K -1.63M -112M -1.66M -11.17M -4.37M -56.23M -4.41M -4.31M -187M
Net Debt	-101K -86.85K -81.61K -74.22K -140K -9.62M -142K -956K -374K -4.82M -378K -369K -16M	367K 317K 298K 271K 510K 35.14M 518K 3.49M 1.37M 17.6M 1.38M 1.35M 58.47M